

HOUSE BILL 325: Opioid Epidemic Response Act.

2019-2020 General Assembly

Committee:		Date:	January 6, 2020
Introduced by:		Prepared by:	Jessica Boney
Analysis of:	S.L. 2019-159		Staff Attorney

OVERVIEW: S.L. 2019-159 removes the registration requirement for buprenorphine prescribers, decriminalizes the use of drug testing equipment, broadens the objectives of syringe exchange programs, and removes the restriction on using State funds to purchase to purchase needles, hypodermic syringes, or other injection supplies.

This act became effective July 22, 2019.

BILL ANALYSIS:

The act does the following:

Part I eliminates the state registration requirement for buprenorphine prescribers.

Part II decriminalizes drug testing equipment used to detect contaminants in controlled substances.

Part III adds reducing the number of drug overdoses in the State to the objectives of syringe exchange programs and removes the restriction on the use of State funds to purchase needles, hypodermic syringes, or other injection supplies.

EFFECTIVE DATE: This act became effective July 22, 2019.

Karen Cochrane-Brown Director



Legislative Analysis Division 919-733-2578

This bill analysis was prepared by the nonpartisan legislative staff for the use of legislators in their deliberations and does not constitute an official statement of legislative intent.